Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EKF Diagnostics’ Cutting-Edge POC Technology on Show at Arab Health

Published: Tuesday, December 18, 2012
Last Updated: Tuesday, December 18, 2012
Bookmark and Share
EKF Diagnostics will be exhibiting its innovative range of products for diabetes and ketosis testing at Arab Health 2013 (28 – 31st January).

As the world's longest running healthcare exhibition and congress, it attracts healthcare professionals from around the world to the International Convention and Exhibition Centre in Dubai. This event will also see the first in a series of worldwide product roadshows to be undertaken by EKF during 2013.

On display at stand RJ15 will be the Quo-Test and Quo-Lab glycated haemoglobin (HbA1c) analysers for near-patient measurement and monitoring of diabetes.  HbA1c monitoring is increasingly used in the detection and management of diabetes and both analysers provide highly accurate, affordable and easy-to-use technology, which uses just 4 µL of venous or finger prick blood to deliver lab-accurate results within four minutes.

The success of EKF’s flagship analyser, the Quo-Test, has resulted in 1,400 units already in use and the CE marked analyser has been approved by China's SFDA for the monitoring of HbA1c in diabetes patients. In July 2012 the small and lightweight Quo-Lab HbA1c analyser was launched. Quo-Lab is designed specifically to meet the needs of clinics and laboratories in emerging economies, where diabetes is an increasingly large public health issue, and is ideal for GP surgeries, diabetes clinics and laboratories.

EKF will also be previewing its first strip-based ketone analyser, the STAT-SiteTM M ßHB, which uses measurements of ß-Hydroxybutyrate (ßHB), the main ketone produced during ketosis, to provide a quantitative and accurate assessment of patients displaying symptoms of ketosis. The technology is changing the way hospitals test for diabetic ketoacidosis and enables testing to move from the laboratory, straight into the emergency room.

The launch of STAT SiteTM M ßHB follows the recent success of the ß-Hydroxybutyrate (ßHB) LiquiColor® Reagent System developed by EKF subsidiary, Stanbio Laboratory, experts in clinical diagnostics for over 50 years and a regular exhibitor at Arab Health. The ßHB liquid stable reagent can be used on any open channel analyser and is used by 13 of the USA’s top 25 diabetes and endocrinology hospitals to provide rapid, objective results.

During the exhibition, EKF Diagnostics will also be running the first event in a series of worldwide roadshows planned for 2013. The roadshows will enable EKF to provide intensive training and support to its distributors, and offer a platform for important dialogue and feedback. The first event, to be held at the Shangri La Hotel in Dubai is already over-subscribed.

Julian Baines, Group CEO, “Following the overwhelming response we received at Medica we are now  looking forward to showcasing our full portfolio of POC solutions at Arab Health for the first time. We are proud of our company’s expert knowledge in blood analysis, which provides cutting edge solutions that are revolutionising the way that conditions such as diabetes and ketosis are being tested, ensuring rapid diagnosis and improved patient outcomes.

We are also delighted by the response to the first of our roadshows. We reached capacity within 24 hours of announcing the event and we’ve had to find an alternative location to meet the demand. This demonstrates that our distributors are confident they can use EKF’s range to grow their own businesses in 2013.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

EKF Diagnostics’ Growth Drives New Role Creation
Expanding business welcomes new faces to further strengthen IVD expertise and new product development.
Saturday, July 18, 2015
EKF Diagnostics Collaborates with Joslin Diabetes Center
Supporting the ongoing clinical and commercial development of early Diabetic Kidney Disease biomarkers.
Monday, November 17, 2014
Studies Validate EKF Diagnostics’ Early Stage Test for Progressive DKD
Independent scientific evidence confirms novel sTNFR1/2 biomarkers can accurately predict end-stage renal disease, up to 10 years in advance.
Friday, May 23, 2014
New Clinical Diagnostics Distributor Program Enhances EKF Customer Service
EKF Diagnostics appoints Simona Carnielli as new EMEA Distribution Manager.
Thursday, May 08, 2014
EKF Diagnostics Acquires Separation Technology
Acquisition complements EKF’s existing offering in the hemoglobin testing market place.
Thursday, March 27, 2014
PointMan™ Enriches Low-level DNA Mutations from Whole Blood
Ultra-sensitive PointMan™ enables blood sampling instead of tissue biopsies for cancer patient mutation status assessment.
Wednesday, January 22, 2014
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Gene That Lowers Heart Attack Risk Identified
Individuals with a rare twelve-letter deletion from a gene on chromosome 17 have significantly reduced non-HDL cholesterol levels and a 35% lower than average risk of heart disease.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
Real-Time Imaging of Embryo Development Could Pave the Way
Researchers at IMCB have developed advanced microscopy technologies to monitor embryo development for more effective human reproduction therapies.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!